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Microglial activation is a central event in neurodegeneration. Novel technologies are sought
for that speciﬁcallymanipulatemicroglial function in order to delineate their role in onset and
progression of neuropathologies.We investigated for the ﬁrst time whether non-viral gene
delivery based on polyethyleneglycol–polyethyleneimine conjugated to the monoclonal
anti-CD11b antibody OX42 (“OX42-immunogene”) could be used to speciﬁcally target
microglia. We ﬁrst conducted immunoﬂuorescence studies with the OX42 antibody and
identiﬁed its microglial integrin receptor CD11b as a potential target for receptor-mediated
gene transfer based on its cellular speciﬁcity in mixed glia culture and in vivo and found
that the OX42 antibody is rapidly internalized and trafﬁcked to acidic organelles in absence
of activation of the respiratory burst. We then performed transfection experiments with
the OX42-immunogene in vitro and in rat brain showing that the OX42-immunogene
although internalized was degraded intracellularly and did not cause substantial gene
expression in microglia. Investigation of speciﬁc barriers to microglial gene transfer
revealed that aggregated OX42-immunogene polyplexes stimulated the respiratory burst
that likely involved Fcγ-receptors. Transfections in the presence of the endosomolytic
agent chloroquine improved transfection efﬁciency indicating that endosomal escape may
be limited. This study identiﬁes CD11b as an entry point for antibody-mediated gene
transfer into microglia and takes important steps toward the further development of
OX42-immunogenes.
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INTRODUCTION
Microglia are the primary immune cells of the central nervous sys-
tem (CNS) and exert many of their important functions through
changes in morphology and gene expression termed “microglial
activation” (reviewed in Ransohoff and Cardona, 2010; Schafer
et al., 2012). It is unclear if activated microglia are neuroprotec-
tive, neurotoxic or neuromodulatory in neuropathology (Saijo and
Glass, 2011; Aguzzi et al., 2013). Thus, methods are being sought
for that allows speciﬁc manipulation of microglial function in
order to gain more insight into their role.
Viruses have been used to manipulate gene expression in
microglial cells. Nevertheless, the development of a virus-based
transgene carrier speciﬁcally targeting microglia has been proven
difﬁcult, because most viruses display broad tropism and there-
fore require extensive modiﬁcation to increase speciﬁcity (Burke
et al., 2002; Cucchiarini et al., 2003; Pfrieger and Slezak, 2012).
Further, the application of viral vectors in vivo was shown
to bear risk of insertional mutagenesis. This was found espe-
cially with lentiviral vectors (Burke et al., 2002; Bokhoven et al.,
2009) that are often used to transfect microglia and other
glial cells in vitro and in vivo (Wrzesinski et al., 2000; Bal-
caitis et al., 2005; Meunier et al., 2007, 2008; McCoy et al., 2008;
Dominguez et al., 2010; Lee et al., 2011; Jiang et al., 2012; Kim
et al., 2012; Liu et al., 2013; Maiorino et al., 2013) and thus limits
their use for other purposes than basic research such as gene
therapy.
Non-viral vehicles have emerged as an alternative for gene
delivery with advantages such as ability to target speciﬁc pop-
ulations of cells and low immunotoxicity compared to viruses
(reviewed in Lv et al., 2006 and Raety et al., 2008). The cationic
polymer polyethyleneimine (PEI) has been frequently used to
bind and condense plasmid DNA (pDNA), to protect it from
degradation and facilitate endosomal escape (Akinc et al., 2005;
Neu et al., 2005; Yue et al., 2011). Further, modiﬁcation of PEI
with polyethyleneglycol (PEG) was demonstrated to add stabil-
ity to PEI complexes by decreasing aggregation (Tang et al., 2003;
Mishra et al., 2004; Millili et al., 2010), reducing PEI-mediated tox-
icity (reviewed in Lungwitz et al., 2005), diminishing non-speciﬁc
interaction of positively charged PEI with negatively charged
proteoglycans on off-target cells (Ogris et al., 2001) and improv-
ing in vivo gene delivery (Germershaus et al., 2006; Duan et al.,
2010).
Non-viral bioconjugates based on PEI–PEG and chemically
linked to monoclonal antibodies for receptor targeting (herein
referred to as “immunogenes”) may be a promising tool for spe-
ciﬁc modulation of microglial function. Antibodies may confer
increased speciﬁcity compared to other ligands such as polysaccha-
rides (Aouadi et al., 2009) and mannose receptor ligands (Ferkol
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et al., 1996, 1998; Kawakami et al., 2000; Markovic et al., 2009)
which bind to receptors that are more ubiquitously expressed.
Such antibody-based vehicles have been successfully applied pre-
viously to deliver genes to several cell lines in vitro (Kircheis
et al., 1997) and motor neurons (Barati et al., 2006) and cholin-
ergic basal forebrain neurons (Berhanu and Rush, 2008) in
vivo.
Antibodies to the integrin receptor CD11b, also known as
complement receptor 3 (CR3), have the potential to beused for tar-
geting immunogenes tomicroglia. TheCD11b receptor is involved
in the immune response of microglia and macrophages of the CNS
and the peripheral immune system, respectively (Akiyama and
McGeer, 1990; Berton and Lowell, 1999; Milner and Campbell,
2002). CD11b expression is up-regulated in activated microglia
in a variety of neuropathological conditions, for instance in the
hypothalamic paraventricular nucleus (PVN) following myocar-
dial infarction (Rana et al., 2010). While immune receptors may
trigger strong pro-inﬂammatory immune responses such as reac-
tive oxygen species (ROS) production and the respiratory burst
(Nimmerjahn and Ravetch, 2008) which are unwanted side-effects
of gene transfer, CD11b is interestingly involved in both, pro-
inﬂammatory (Block et al., 2007; Pei et al., 2007; Zhang et al.,
2007; Hu et al., 2008; Davalos et al., 2012) and anti-inﬂammatory
(Grifﬁths et al., 2009; Amarilyo et al., 2010; Ricklin et al., 2010)
immune functions in microglia that seem to depend on the recep-
tor binding site (Veˇtvcˇka et al., 1996; Xia et al., 1999; Ross, 2000)
and interactions with other co-receptors such as Fcγ-receptors
(Huang et al., 2011). More importantly, parasites and bacteria
utilize CD11b to infect host cells and to avoid intracellular degra-
dation (Mosser and Edelson, 1987; Hajishengallis and Lambris,
2011) indicating that CD11b may be also an entry point for
antibody-mediated delivery of transgenes into microglia. The
monoclonal antibody OX42 targets CD11b (Robinson et al., 1986)
and is suggested to bind at or close to a site of CD11b related
to its anti-inﬂammatory properties (Klegeris and McGeer, 1994;
Sohn et al., 2003). Thus, OX42 may be suitable as a target-
ing ligand for microglial-speciﬁc gene delivery combined with
the ability of PEI–PEG to bind, protect and transfer DNA into
cells.
We thus propose to determine the speciﬁcity and suitabil-
ity of the monoclonal antibody OX42 as a targeting agent for
immunogenes for microglia and whether a targeting bioconjugate
(“OX42-immunoporter”) could be used for speciﬁc microglial
transfection. Immunoﬂuorescence studieswith labeledOX42 anti-
body were conducted in cultured glia cells as well as in vivo
to determine the speciﬁcity of CD11b for microglia, the ability
of CD11b to internalize the antibody and its intracellular local-
ization. Subsequent transfection experiments with the targeting
bioconjugate were then conducted in vitro and in vivo utilizing
immunohistochemistry (IHC) to determine successful microglial
transfection. The activation of the respiratory burst by aggregated
polyplexes as measured by dynamic light scattering (DLS) and
an assay for ROS as well as limited endosomal escape as deter-
mined by transfections in presence of the endosomolytic agent
chloroquine was then investigated to identify potential microglia-
speciﬁc barriers to non-viral gene transfer. This study is the ﬁrst
to describe CD11b as a target on microglia for receptor-mediated
gene transfer and to identify microglia-speciﬁc barriers that will
lead to further development of targeting non-viral gene vehicles
for microglial gene transfer.
MATERIALS AND METHODS
ANIMAL ETHICS
All procedures performed on animals were approved by the RMIT
University Institutional Animal Experimentation Ethics Commit-
tee or the Alfred Medical Research and Education Precinct Animal
Ethics Committee and conformed to the National Health and
Medical Research Council of Australia code of practice for the
care and use of animals for scientiﬁc purposes.
EXPERIMENTAL OVERVIEW
In vitro experiments for speciﬁcity and internalization of theOX42
antibody as well as transfections were performed in mixed cultures
and isolated microglia obtained from 1 to 3 day old Sprague-
Dawley rat brains as outlined in Section “Primary Cell Culture.”
A total of ﬁve brains of 9–10 weeks old male Sprague-Dawley rats
(300–350 g) were used to test speciﬁcity of CD11b for microglia
and for in vivo transfections. Studies on barriers to microglial
transfections in vitro utilized mixed glia cultures and isolated
microglia.
PRIMARY CELL CULTURE
Mixed glia cultures were prepared from neonatal Sprague-Dawley
rat brains (days 1–3) based on the method developed by Nakajima
et al. (1989). Brieﬂy, a cell suspension was obtained by com-
bination of mechanical and enzymatical (0.16% trypsin/0.01%
deoxyribonuclease I, Sigma) dissociation of brain tissue. Mixed
glia cultures were maintained in Dulbecco’s Modiﬁed Eagle
Medium with high glucose (DMEM, GibcoTM) supplemented
with 10% fetal bovine serum (FBS, Bovogen) and 2% penicillin-
streptomycin (GibcoTM) in poly-D-lysine (PDL, Sigma)-coated
tissue culture ﬂask (25 cm2, TPP) exchanging half of the cell cul-
ture medium twice a week. Microglial cells appeared on top of
an astrocytic layer after a few days and were available in sufﬁcient
amounts for isolation after 8–12 days. For immunoﬂuorescence
studies and transfections that involved mixed glia cultures, mixed
cultures were prepared as above, but plated on PDL-coated cover-
slips in 24-well plates. Mixed cultures were used for experiments
3–4 days thereafter.
Microglial cells were isolated from mixed cultures by shaking
the cell culture ﬂasks at 37◦C for 60 min (120 rpm). Dependent
on the experiment, isolated microglia (>98% pure, determined by
CD11b-immunoreactivity with OX42 antibody, data not shown)
were either plated on PDL-coated coverslips (2 × 104 cells/well),
onto PDL-coated ﬂuorodishes (World Precision Instruments,
5 × 104 cells/dish) or in PDL-coated black 96-well plates (Greiner,
1 × 104 cells/well).
ANTIBODY PURIFICATION AND LABELING
OX42 and X63 antibody secreting hybridoma cell lines were grown
in RPMI-1640 GlutaMax medium supplemented with 10% FBS,
1× penicillin-streptomycin-glutamine and 1× hypoxanthine-
thymidine (GibcoTM). The antibody X63 has no known antigen
and was used as non-speciﬁc control IgG. Monoclonal antibodies
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were puriﬁed from supernatant using protein G (Millipore)
according to the manufacturer’s instructions.
Antibodies were labeled according to manufacturer’s instruc-
tions with either N-hydroxysuccinimide (NHS)-activated ﬂuores-
cein or Alexa 488 sulfodichlorophenol (SDP) ester (Molecular
Probes®). Tagged antibodies were puriﬁed on PD10 desalting
columns (GE Healthcare). The ﬂuorophore to protein (F/P) ratios
obtained were F/P = 9 for OX42-FITC, 5 for OX42-Alexa488, and
4 for X63-Alexa488.
IMMUNOCYTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY
Double-labeling experiments in mixed glia culture and in brain
slices were performed to either determine speciﬁcity of OX42 anti-
body for microglia or assess transfections in vitro and in vivo.
Cultures were ﬁxed [4% paraformaldehyde (PFA), Merck] and
then blocked for 30 min (10% normal horse serum, 0.1% Triton-
X100, Sigma), while brain sections were blocked in 10% normal
horse serum containing 0.5% Triton-X100 (1 h, room temper-
ature). Antibodies against cell markers (Table 1) were used to
detect astrocytes [anti-glial ﬁbrillary acidic protein (GFAP)] and
microglia [ionized calcium binding adapter molecule 1, (Iba1); or
CD11b]. Green ﬂuorescent protein (EGFP) expression in trans-
fected cells was conﬁrmed with a monoclonal mouse anti-EGFP
antibody. Labeled secondary antibodies were applied to visualize
primary antibody binding.
All antibody incubations in mixed culture were performed for
1 h at room temperature. For IHC, primary antibodies were incu-
bated for 3 days at 2–8◦C in a humidifying chamber and secondary
antibodies applied thereafter for 2 h at room temperature followed
by 1 h incubation with extravidin-Cy3 conjugate. Cell nuclei were
counter-stained with Hoechst dye (1:500, 10–25 min).
Speciﬁc staining by primary antibodies was demonstrated in
vitroby following the same immunostainingmethods but omitting
the primary antibodies (data not shown). Each condition was
run on duplicate coverslips in each experiment and at least three
experiments were performed.
CELLULAR DISTRIBUTION OF CD11b IN VIVO
Male Sprague-Dawley rats (300–350 g) were stereotactically
injected under isoﬂurane anesthesia with 250–300 nL of Alexa
488-labeled OX42 antibody (right side) or Alexa 488-labeled X63
antibody (left side) into the PVN of the hypothalamus of the same
animal (0.6 mm lateral from midline, 8.0 mm depth, –2.1 mm
posterior from Bregma). Animals were kept anesthetized and per-
fused (4% PFA, Merck) 3 h after injections before brains were
collected and post-ﬁxed for 4 h. After 3–4 days of storage in 30%
sucrose, 30 μm brain sections were cut on a cryostat, placed on
gelatin-coated microscope slides and IHC performed. Two ani-
mals were injected and localization of OX42 antibody was assessed
qualitatively by IHC.
INTERNALIZATION OF OX42 ANTIBODY
Isolatedmicroglial cells on coverslipswere incubatedwith 2μg/mL
FITC-tagged OX42 antibody at 37◦C, ﬁxed after 5, 10, 20, and
60min and nuclei stainedwithHoechst 34580 (Molecular Probes®
1:500, 10 min). Control cells were incubated for 30 min on ice.
Non-speciﬁc internalization of antibody was examined by incu-
bating microglia with Alexa 488-labeled X63 antibody (60 min,
37◦C). The average green ﬂuorescence was measured in the perin-
uclear region of each cell after background subtraction. Three
independent experiments were performed (n ≥ 77 cells per
condition). Antibody internalization was quantiﬁed (ImageJ) as
the increase in intracellular ﬂuorescence by accumulated OX42
antibody in the perinuclear region. One-way analysis of vari-
ance (one-way ANOVA) and post hoc one-sample t-tests with
Bonferroni correction were used to assess signiﬁcance.
TRAFFICKING OF OX42 ANTIBODY
Isolated microglial cells on ﬂuorodishes were incubated with
2 μg/mL OX42-Alexa 488 for 30 min on ice to saturate membrane
CD11b. Cells werewashed to remove unbound antibody and inter-
nalized antibody chased for further 60 min at 37◦C. Cell nuclei
(Hoechst) and acidic vesicles (Lysotracker Red, 50 nM, Molecular
Table 1 | Antibodies and reagents used for immunostaining.
Target Antibody Tag Host Use c/DF Source
CD11b OX42 – Mouse ICC 1.25 μg/mL RMIT
Iba1 α-Iba1 – Goat ICC 400 Abcam
IHC 100
GFAP α-GFAP – Rabbit ICC/IHC 150 Life Technologies
EGFP α-GFP – Mouse ICC 400 Roche
IHC 200
Mouse IgG α-mouse Alexa488 Donkey ICC 400 Life Technologies
Mouse IgG α-mouse Biotin Horse ICC 400 Vector Labs
Goat IgG α-goat Biotin Horse ICC 400 Vector Labs
Rabbit IgG α-rabbit Alexa594 Donkey ICC/IHC 400 Life Technologies
Biotin Extravidin Cy3 – ICC/IHC 600 Sigma
c, concentration; DF, dilution factor; ICC, immunocytochemistry; IHC, immunohistochemistry; GFAP, glial ﬁbrillary acidic protein; Iba1, ionized calcium binding adapter
molecule 1.
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Probes®) were stained for 5 min at 37◦C, extracellular ﬂuores-
cence quenched with 0.2% trypan blue and cells imaged. Two
experiments were performed and results assessed qualitatively.
OX42-IMMUNOPORTER CONJUGATION
OX42 antibody in HEPES-buffered saline (HBS), pH 7.9, was
modiﬁed with 10 mM N-Succinimidyl 3-(2-pyridyldithio)-
propionate NHS ester (SPDP, ThermoFisher) at a ratio of
1.3 μL SPDP/mg OX42 for 2 h at room temperature. SPDP-
modiﬁed antibody was desalted on PD-10 columns, pro-
tein positive fractions identiﬁed (DC-Protein Assay, Bio-
Rad), pooled and antibody concentration estimated on a
spectrophotometer (280 nm). Absorbance of the leaving
group pyridine-2-thione was measured at 343 nm to calcu-
late conjugation efﬁciency at the end of the immunoporter
synthesis.
Branched 25 kDa PEI (Sigma) was dissolved in ultrapure
water, neutralized with concentrated HCl, and desalted and
buffer exchanged on PD-10 columns to HBS, pH 7.9. PEI-
containing fractions were pooled and the PEI-concentration
estimated with a TNBS-assay (2,4,6-trinitrobenzene sulfonic acid,
Sigma) described by Snyder and Sobocinski (1975) and adapted
for 96-well microplates.
Neutralized PEI was engrafted with PEG by incubating PEI
with a 7.5 molar excess of 125 mM NHS-activated TMS(PEG)12
(ThermoFisher) for 1 h at room temperature under nitrogen
atmosphere. Under these reaction conditions, 12 PEG molecules
bind to 1 molecule of PEI (data not shown). PEI–PEG was then
puriﬁed on a PD-10 desalting column and PEI content estimated
with a TNBS-assay.
PEI–PEG was modiﬁed with SPDP by incubating PEI–PEG in
HBS (pH 7.9) with 5 μL of 10 mM SPDP per milligram PEI–
PEG for 1 h at room temperature. SPDP-modiﬁed PEI–PEG
was desalted on a PD-10 column and an excess of 150 μL of
25 mg/mL dithiothreitol (DTT, Sigma) added to activate SPDP-
modiﬁed PEI–PEG. The mixture was incubated for 1 h at room
temperature under nitrogen atmosphere. After reaction, the mix-
ture was desalted to remove cleaved pyridine 2-thione and DTT.
PEI-concentration was estimated with a TNBS-assay. Activated
SPDP-modiﬁed PEI–PEG were prepared immediately before con-
jugation to avoid extended exposure to air and oxidization of the
reactive sulfhydryl-group.
SPDP-modiﬁed OX42 antibody and activated SPDP-modiﬁed
PEI–PEG were incubated overnight at a molar ratio of OX42
to PEI–PEG of 1:3. Incubation was done at room tempera-
ture under nitrogen in presence of 0.1 mM ethylenediaminete-
traacetic acid (EDTA, Sigma). After incubation, the reaction
mixture was desalted and protein-positive (280 nm) as well as
pyridine-2-thione positive fractions (343 nm) pooled separately.
Conjugated OX42-immunoporter was puriﬁed in a ﬁrst step
with a HiTrap SP/HP cation exchange column (GE Healthcare)
using increasing molarities of salt (0.5–3 M NaCl). The eluted
OX42-immunoporter conjugate was then puriﬁed in a second step
on a HiLoad 16/60 Superdex 200 gel ﬁltration column (GE Health-
care) connected to a FPLC (BioLogicDuoFlow,Bio-Rad). Theﬁnal
bioconjugate was concentrated with 100 kDa ultraﬁltration spin
columns (Millipore) to 2–3 mg/mL in HBS, pH 7.3.
The averagemolar ratio of conjugatedOX42 antibody and PEI–
PEG was calculated based on the release of pyridine-2-thione
according to the manufacturer’s instructions and found to be
n = 1.1. The yield of conjugated OX42-immunoporter was 40%.
PLASMID DNA CLONING AND PURIFICATION
Plasmid DNA was cloned and subcultured in competent DH5α
Escherichia coli cells (Life Technologies) using standard proce-
dures. An enhancedEGFP-expressing plasmid (pEGFP-N1, 4.7 kb)
was a gift from Dr. W. Kruger (RMIT University, Melbourne) and
was puriﬁed with NucleoBond® PC 2000 Kit (Macherey-Nagel)
according to the manufacturer’s instructions. The purity of plas-
mid preparations was A260/280 ≥ 1.9 for all preparations and the
integrity of sub-cloned pEGFP-N1 was conﬁrmed by restriction
enzymeanalysis. A control vector pcDNA3.1/Zeo(+; 5.0 kb)which
lacks the EGFP genewas a gift fromDr. H.Cuny (RMITUniversity,
Melbourne).
GEL RETARDATION ASSAYS
The ability of PEI polyplexes to bind DNA (400 ng/well) was tested
at nitrogen/phosphate (N/P) ratios of 2–10. TheN/P-ratiowas cal-
culated by taking into account themolar concentration of nitrogen
residues (23.2 mmol/L) of 25 kDa branched PEI and a phosphate
content of 3 nmol per 1μg nucleic acid. PEI-conjugates and pDNA
(0.1 mg/mL in HBS, pH 7.3) were mixed to form PEI-pDNA com-
plexes and incubated at room temperature for 30 min. Gel loading
buffer (10X BlueJuiceTM, Life Technologies) was added and sam-
ples run on a 0.8% agarose gel (Promega) for 40–60 min at 100 V.
Imageswere acquired on aﬂuorometer afterDNAstaining (SYBR®
Safe DNA, Life Technologies).
POLYPLEX PREPARATION AND TRANSFECTION EXPERIMENTS
PEI–PEG and OX42-immunogene polyplexes were prepared at an
N/P-ratio of 4. Transfectants (0.5 mg/mL in HBS) were added
slowly to pDNA (0.5 mg/mL in HBS) and incubated for 15 min
without vortexing. For in vitro transfections (20 μg DNA per
well), complete cell culture medium (DMEM with 10% FBS)
was then added to a total volume of 0.5 mL and the solution
mixed by pipetting up and down. After removing the astrocyte-
conditioned medium, mixed glia cultures were incubated with
polyplexes for 16–24 h. For transfections performed in the pres-
ence of 100 μM chloroquine (Sigma), transfection medium was
removed after 4 h. After removal of transfectants, a 1:1 mixture of
fresh complete medium and astrocyte conditioned medium was
added and cells were ﬁxed (4% PFA, 10 min) after a total of 72 h
and immunostaining performed.
Polyplexes were injected into three different brain regions of
individual Sprague-Dawley rats (300–350 g). PEI–PEG andOX42-
immunogene polyplexes were injected into the PVN (200 ng DNA;
left side: PEI–PEG, right side: OX42-immunogene) or dorsal stria-
tum (300 ng DNA). Three microgram of DNA were injected
with the OX42-immunogene into the right lateral ventricle. Rats
were perfused after 72 h and brain sections obtained as outlined
in Section “Cellular Distribution of CD11b In Vivo” and IHC
performed.
Transfection efﬁciency and speciﬁcity of PEI–PEG and OX42-
immunogene in vitro was assessed by cell counting and was
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based on cell type speciﬁc markers. Values were expressed as
mean ± standard error of mean (SEM) and signiﬁcance assessed
with either a Student’s t-test or one-way ANOVAs with post hoc
t-tests with Bonferroni correction or post hoc one-sample t-tests
with Bonferroni correction.
STUDY OF OX42-IMMUNOGENE AGGREGATION BY DYNAMIC LIGHT
SCATTERING
The size-distribution proﬁle of the OX42-immunogene poly-
plexes was investigated by adding complete cell culture medium
(DMEM with 10% FBS), OX42-immunoporter (10.3 μg) and
pDNA (20 μg, to form OX42-immunogene) in this order to the
measurement vial used for DLS. The effect of diluents on OX42-
immunogene aggregationwas determined by addingHBS,DMEM
(+FBS) or DMEM (–FBS) after polyplex maturation in HBS or
DMEM (+FBS).
Raw data was acquired for 30 s for each measurement (three
measurements per experiment) with a Fast DLS analyser (ALV
GmbH, Germany). Intensity weighted size-distribution proﬁles
were obtained from correlation functions using ALV-Correlator
Software (ALV GmbH). The hydrodynamic diameter with the
highest intensity for each experiment was obtained by averaging
the values from the three separate measurements. Polyplexes were
prepared twice for each experimental condition.
MEASUREMENT OF REACTIVE OXYGEN SPECIES PRODUCTION
A 96-well plate assay was developed to measure ROS produc-
tion using the ROS-sensitive dye CM-H2DCFDA [5-(and-6)-
chloromethyl-2′,7′-dichloro-dihydro-ﬂuorescein diacetate, acetyl
ester; Molecular Probes®] which responds to intracellular oxida-
tion with increase in ﬂuorescence of its product DCF. Microglia
were loaded with 5 μM dye in Krebs-HEPES-buffer (KHB) and
incubated for 30 min (37◦C). One microgram of OX42 antibody
and non-viral vehicles (N/P = 4) were added to the wells and
incubated at 37◦C. Particulate zymosan A (Sigma, 1.5 μg/well)
was used as positive control to trigger the respiratory burst and
the NADPH oxidase inhibitor diphenyliodonium (DPI, Sigma)
was used at 1 μM to abolish ROS production. Fluorescence was
read on a plate reader (FlexStation 3) after 60 min. Baseline ﬂuo-
rescence values (KHB only) were subtracted and results expressed
as percentage of the response to 100 ng/mL of the protein kinase
C (PKC) activator phorbol-12,13-dibutyrate (PDBu, Enzo Life
Sciences) which was used to normalize the responsiveness of dif-
ferent batches of isolated microglial cells. Results were expressed
as mean ± SEM (n = 4–7 experiments in quadruplicate mea-
surements) and signiﬁcant ROS production was assessed with
a one-way ANOVA test using post hoc one-sample t-tests with
Bonferroni correction.
RESULTS
INTEGRIN CD11b IS EXPRESSED IN MICROGLIA BUT NOT IN
ASTROCYTES
In order to develop microglia-speciﬁc vehicles for gene delivery
with the OX42 antibody, we ﬁrst investigated the cellular distri-
bution of the target receptor CD11b. CD11b-immunreactive cells
in mixed culture stained positive for Iba1 protein (Figure 1A).
However, cells that expressed GFAP protein were not positive for
CD11b (Figure 1B). This conﬁrmed that CD11b expression is
speciﬁc for microglia in vitro and that OX42 antibody binds to
microglial cells only.
When Alexa 488-tagged OX42 and X63 antibodies where
injected into rat brain, OX42-Alexa 488 showed strong green
ﬂuorescence and labeled many cells that appeared to be non-
activated microglia with small cell bodies and long, ﬁne pro-
cesses (Figures 1C,D). However, X63-Alexa 488 ﬂuorescence
was only visible along the needle track and this control anti-
body did not bind to cells distant to the injection site (data
not shown). Immunohistochemistry for microglia and astrocytes
showed that the injected OX42 antibody speciﬁcally bound to
microglial cells, because CD11b-positive cells also immunostained
for Iba1 (Figure 1C). However, CD11b-IR did not co-localize with
GFAP-positive astrocytes (Figure 1D). Thus, the in vivo data con-
ﬁrmed the speciﬁcity of CD11b for microglia, consistent with
results obtained from immunoﬂuorescence studies in cultured
cells.
OX42 IS INTERNALIZED INTO MICROGLIA VIA CD11b RECEPTOR AND
TRAFFICKED TO LYSOSOMES
While speciﬁcity of an antibody is an important aspect for non-
viral gene delivery, internalization of OX42 is required to deliver
genes into the cell. Live cell experiments demonstrated that strong
vesicle-like ﬂuorescence accumulated in the perinuclear region
of isolated microglial cells (Figure 2A). As a control, microglia
were incubated with OX42-FITC on ice to halt internalization.
Microglia exhibited CD11b-IR only in the cell membrane under
this condition (Figure 2A) conﬁrming that OX42 binds to an
extracellular epitope of CD11b. Alexa 488-tagged X63 antibody
did not bind nor was internalized into microglia after 60 min
(Figure 2A) suggesting that the uptake of OX42 antibody is medi-
ated by the CD11b receptor and does not occur via other receptors,
for instance Fcγ-receptors, or other non-speciﬁcmechanisms such
as pinocytosis.
Internalization of OX42 antibody was further investigated
in a time-lapse experiment. After the initial 5 min incuba-
tion period, OX42-FITC ﬂuorescence in the perinuclear region
increased rapidly and signiﬁcantly (10 min: 163 ± 18 AU;
20 min: 232 ± 26 AU; 60 min: 448 ± 50 AU; P < 0.0001;
Figure 2B).
In order to investigate the intracellular fate of internalized
OX42 antibody, internalization experiments were repeated with
Alexa 488-tagged OX42 antibody due to the pH-dependence of
FITC ﬂuorescence. Microglial cells were co-labeled with Lyso-
tracker Red, a dye that accumulates in acidic vesicles and is
often used to visualize lysosomes. OX42-Alexa 488 antibody
accumulated in perinuclear vesicles after 60 min (Figure 2C) as
observed in previous internalization assays. Antibody-containing
vesicles were essentially all positive for Lysotracker Red staining
demonstrating that internalized OX42 antibody is trafﬁcked to
acidic organelles that most likely represent late endosomes and
lysosomes. Quenching the extracellular ﬂuorescence further con-
ﬁrmed that the observed perinuclear ﬂuorescence originates from
intracellular vesicles (Figure 2C).
In summary, these experiments demonstrated that the OX42
antibody may be a suitable ligand for non-viral gene delivery into
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FIGURE 1 | Integrin receptor CD11b is specific for microglia in vitro
and in vivo. (A) CD11b-positive cells (green) in mixed glia culture stained
for the selective microglia marker Iba1 (red). Many cells that stained for
the nuclear dye Hoechst were negative for CD11b and Iba1 (white arrow
heads). (B) GFAP-positive cells (red) did not immunostain for CD11b
(green) in vitro. (C) Immunohistochemistry of rat brains injected with
OX42-Alexa 488 (green) demonstrated co-labeling with microglial marker
Iba1 (red, white arrow heads). (D) GFAP-IR (red) and CD11b-IR (green) did
not co-localize showing that astrocytes do not express CD11b or take up
OX42 antibody.
microglia. Thus, a microglia-targeting OX42-immunoporter was
developed by conjugating the OX42 antibody to PEG-engrafted
PEI (PEI–PEG) via the hetero-bifunctional linker SPDP.
THE OX42-IMMUNOPORTER BINDS PLASMID DNA
The ability of the OX42-immunoporter bioconjugate to bind
pDNA and form the OX42-immunogene was tested in gel retar-
dation assays. OX42-immunoporters as well as PEI and PEI–PEG
were able to bind plasmid DNA with increasing Nitrogen (PEI)
to Phosphate (plasmid DNA; N/P) ratios (Figure 3). The OX42-
immunoporter vehicle completely retarded pDNA at N/P = 5.
THE OX42-IMMUNOGENE REDUCES OFF-TARGET TRANSFECTION IN
VITRO
Transfection efﬁciency and speciﬁcity of the targeting OX42-
immunogene vs. non-targeting PEI–PEG were then compared in
mixed glia culture. PEI–PEG transfected Iba1-IR microglia (yel-
low arrow heads) and GFAP-IR astrocytes (white arrow heads)
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FIGURE 2 | OX42 antibody is internalized into microglia and
accumulates in perinuclear acidic vesicles. (A) Microglial cells incubated
(Continued)
FIGURE 2 | Continued
on ice with OX42-FITC (green) immunostained for CD11b in the membrane
only. Microglia incubated with OX42-FITC at 37◦C showed green
ﬂuorescent vesicles close to the cell nucleus (Hoechst-dye, blue) indicating
the uptake of OX42 antibody into microglia. The negative control antibody
X63 did not bind and internalize in microglia. (B) Quantiﬁcation of FITC
ﬂuorescence demonstrated a rapid increase and accumulation of OX42
antibody in the perinuclear region of microglia. (C)The internalization of
OX42 antibody was conﬁrmed by quenching the extracellular ﬂuorescence
with trypan blue. Confocal images revealed that OX42 antibody
accumulates in perinuclear acidic vesicles in microglial cells as observed by
the co-localization of the acidic organelle marker Lysotracker Red. Values are
plotted as Mean ± SEM. n ≥ 77 cells per time-point. ****P < 0.0001 vs.
control; N.S., not signiﬁcant; AUs, arbitrary units.
as shown by EGFP-speciﬁc green ﬂuorescence (Figure 4A, upper
panel). The OX42-immunogene transfected very few cells in vitro
and only some of them were potentially GFAP-negative microglia
(yellow arrow heads), others were GFAP-positive astrocytes (white
arrow heads, Figure 4B, lower panel). Quantiﬁcation revealed that
PEI–PEG transfected signiﬁcantlymore cells per coverslip than the
OX42-immunogene (214 ± 37 vs. 5 ± 2, P < 0.005, Figure 4B).
However, 80–90% of PEI–PEG-transfected cells were GFAP-IR
astrocytes and not microglia (data not shown). Through incor-
poration of the OX42 antibody into the non-viral vehicle, the
OX42-immunogene decreased the number of transfected cells sig-
niﬁcantly, but approximately 4 out of 5 transfected cells were still
GFAP-IR astrocytes. Thus, the OX42-immunogene reduced off-
target gene delivery into astrocytes, but did not cause substantial
gene expression in microglia.
INGESTION OF THE OX42-IMMUNOGENE IS ASSOCIATED WITH
INCREASE OF NON-SPECIFIC FLUORESCENCE
The low number of cells that were transfected with the OX42-
immunogene prompted an investigation of the cause of the lack
of EGFP expression in microglia. Confocal images at lower magni-
ﬁcation demonstrated that PEI–PEG caused green ﬂuorescence of
different intensities (yellow and blue arrow heads, Figure 5A). In
OX42-immunogene treated cells,mainly green ﬂuorescence of low
intensity was observed (blue arrow heads, Figure 5A) and this ﬂu-
orescence was almost exclusively seen in GFAP-negative microglia
(Figure 5A).
At higher magniﬁcation and increased laser power and gain
(Figure 5B), cells that exhibited high intensity of green ﬂuo-
rescence were also IR for an anti-EGFP antibody (Figure 5B).
EGFP-speciﬁc ﬂuorescence was distributed within the cytoplasm
and cell nucleus in PEI–PEG transfected cells. In contrast, the
green ﬂuorescence of low intensity was vesicle-like, concentrated
around the cell nucleus and EGFP-IR was absent (Figure 5B).
This indicated that the non-speciﬁc ﬂuorescence is unrelated to
EGFPexpression. CD11b-immunoreactivemicrogliawere thepre-
dominant cell type that displayed non-speciﬁc ﬂuorescence upon
treatment of mixed cultures with non-viral vehicles (yellow arrow
heads, Figure 5B).
In order to ﬁrmly establish that the non-speciﬁc ﬂuorescence
was unrelated to EGFP-expression, mixed cultures were trans-
fected as previously but delivering an empty control vector that
lacked the EGFP reporter gene. After 3 days, PEI–PEG and
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FIGURE 3 | Gel retardation assay demonstrates the ability of
the OX42-immunoporter in binding and retarding plasmid DNA.
Non-linearized pDNA alone (lane 2) migrated in two main bands. PEI (lanes
3–5) and PEI–PEG (lanes 6–8) completely retarded plasmid DNA at
N/P-ratios of ≥5. The OX42-immunoporter (lanes 9–12) bound and retarded
DNA with increasing N/P-ratios forming an OX42-immunogene. PEI,
polyethyleneimine; PEG, polyethylene glycol; IP, immunoporter; bps, base
pairs; pDNA, plasmid DNA.
OX42-immunogene treated cultures exhibited the same pattern
of non-speciﬁc ﬂuorescence (Figure 6) as observed in cultures
treated with the transfectants carrying the EGFP-expressing plas-
mid (Figures 5A,B). This non-speciﬁc ﬂuorescence was localized
in GFAP-negative microglia, while untreated control cells had
only a very low level of non-speciﬁc background ﬂuorescence
(Figure 6). Thus, the increase in intracellular, non-speciﬁc ﬂu-
orescence was due to treatment of mixed cultures with PEI–PEG
and the OX42-immunogene and it indicated that PEI–PEG and
the OX42-immunogene were internalized but failed to cause gene
expression in microglia
THE OX42-IMMUNOGENE DOES NOT TRANSFECT MICROGLIA IN VIVO
Whether the inability of the OX42-immunogene to cause EGFP
expression in microglia was an artifact of the in vitro test system or
reﬂected the actual inability of theOX42-immunogene to transfect
microglia was investigated in vivo by injecting PEI–PEG and the
OX42-immunogene into different brain areas.
PEI–PEG and the OX42-immunogene injected into the PVN
(data not shown) caused an increase in green ﬂuorescence as
observed after injections of the OX42-immunogene into the right
lateral ventricle (Figure 7A) and the dorsal striatum (Figure 7B).
The majority of cells displaying green ﬂuorescence were Iba1-IR
microglial cells (yellow arrow heads, Figure 7A) that acquired a
round amoeboid or phagocytic shape. Astrocytes did not exhibit
green ﬂuorescence (data not shown). The green ﬂuorescence
seen in microglia appeared to be non-speciﬁc as judged by the
vesicle-like structure and absence of ﬂuorescence in the nucleus
as observed in EGFP-transfected cells in vitro (Figure 5B). After
OX42-immunogene injection into the dorsal striatum, absence
of EGFP-expression was demonstrated in brain sections either
imaged directly without performing IHC or immunostaining with
a mouse anti-EGFP antibody (Figure 7B). In absence of cell type
speciﬁc markers, the ﬂuorescence observed was non-speciﬁc and
also seen in the red ﬁlter. Further, EGFP-IR was not observed
either (Figure 7B) demonstrating that EGFP was not expressed
in vivo. Further, the absence of an increased red ﬂuorescence
due to the secondary anti-mouse antibody also suggested that the
OX42-immunogene was degraded, because the secondary anti-
body did not cross-react with the OX42 antibody component
of the immunogene. Thus, the absence of EGFP-expression in
microglia in vivo was consistent with the lack of EGFP-expression
in vitro.
OX42-IMMUNOGENE AGGREGATES TRIGGER THE RESPIRATORY BURST
IN MICROGLIA
The uptake of the non-viral vehicles into microglia, the apparent
intracellular degradation concomitant with increase in non-
speciﬁc ﬂuorescence and the absence of widespread gene expres-
sion in microglia prompted an investigation into the reasons
of this phenomenon. Initial experiments aimed at determin-
ing the size-distribution proﬁles for the OX42-immunogene
formed in complete cell culture medium (DMEM with 10%
FBS, Figure 8A). Complete cell culture medium contained small
aggregates of <100 nm in diameter (Figure 8A). There was no
marked difference in the size-distribution proﬁle when the OX42-
immunoporter was added suggesting that the vehicle had not
substantially aggregated. However, when pDNA was added to
form the OX42-immunogene complex (N/P = 4), large OX42-
immunogene aggregates formed over a wide diameter range
(≈50–1300 nm,Figure 8A). Based on the aggregate sizes observed,
this suggested that the OX42-immunogene could potentially
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FIGURE 4 |The OX42-immunogene reduces off-target transfection of
PEI–PEG in vitro. (A) Representative confocal images of transfected cells
in mixed culture. Non-targeting PEI–PEG (upper panel) transfected few
microglial cells (yellow arrow heads) with an EGFP reporter plasmid as
judged by EGFP ﬂuorescence (green). EGFP-transfected cells were either
Iba1-immunoreactive (IR, red, microglia) or lacked GFAP expression (red).
PEI–PEG also transfected GFAP-IR astrocytes (white arrow heads). The
targeting OX42-immunogene (lower panel) transfected few GFAP-negative
cells that potentially are microglial cells (yellow arrow heads), but it also
delivered the reporter gene into few GFAP-IR astrocytes (white arrow
heads). (B) Quantiﬁcation of transfected cells per coverslip. PEI–PEG
(214 ± 37 cells) transfected signiﬁcantly more cells than the
OX42-immunogene (5 ± 2 cells). Values are plotted as Mean ± SEM.
***P < 0.005. n = 6 coverslips for PEI–PEG and n = 4 coverslips for
OX42-immunogene. EGFP, green ﬂuorescent protein; GFAP, glial ﬁbrillary
acidic protein.
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FIGURE 5 |The OX42-immunogene is taken up in microglia but does not
cause gene expression in vitro. (A) PEI–PEG transfected few GFAP-negative
(red) cells that potentially are microglia. Green ﬂuorescence of high (yellow
arrow heads) and low intensity (blue arrow heads) was visible for mixed
cultures treated with either PEI–PEG or the OX42-immunogene. The green
ﬂuorescence of low intensity almost exclusively co-localized with
GFAP-negative cells (blue arrow heads). (B)The green ﬂuorescence of high
intensity was EGFP-speciﬁc (green) and visible in the cytoplasm and cell
nucleus. Speciﬁc ﬂuorescence caused by EGFP-expression was conﬁrmed
with an anti-EGFP antibody (red). The green ﬂuorescence of low intensity was
unrelated to EGFP-expression (non-speciﬁc) as it did not co-localize with
EGFP-IR. Non-speciﬁc ﬂuorescence (green) was mainly localized in CD11b-IR
microglia (red), appeared vesicle-like and accumulated in the perinuclear
region. Note: when imaging non-speciﬁc ﬂuorescence, laser power and gain
were increased compared to imaging EGFP-speciﬁc ﬂuorescence by confocal
microscopy.
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FIGURE 6 |Transfection experiments with a control vector that lacked the EGFP reporter gene caused an increase in non-specific fluorescence after
treatment with PEI–PEG and the OX42-immunogene. Untreated control mixed cultures displayed very low levels of non-speciﬁc green background
ﬂuorescence.
be internalized via receptor-mediated endocytosis, but larger
aggregates could trigger phagocytosis in microglia.
Further experiments were designed to understand how the
aggregation behavior of the OX42-immunogene depended on
sample preparation. The mode of OX42-immunogene aggregate
size was found to be strongly dependent on FBS, either added as
diluent after maturation of complexes in HBS or already present
in the maturation buffer (Figure 8B). Although FBS caused a shift
in the size-distribution proﬁle to smaller aggregates, it did not
markedly narrow the size-distribution (Figure 8B). DLS results
further suggested that the absence of FBS for in vivo transfections
would cause the formation and injection of larger aggregates as
compared to in vitro transfections where the OX42-immunogene
was formed in HBS, but FBS-containing cell culture medium was
added to a ﬁnal concentration of 9% FBS in the transfection
medium.
The consequences of microglial phagocytosis of aggregated
polyplexes were then investigated by measuring the production
of ROS. There was a signiﬁcant increase in the observed ﬂu-
orescence of the ROS indicator in microglia treated with the
OX42-immunogene (38.8 ± 3.3%, P < 0.0001; Figure 8C).
DPI (1 μM), an inhibitor of the respiratory burst, abolished
ROS production in microglia elicited by the aggregated OX42-
immunogene (–7.02 ± 4.49%). Non-targeting PEI–PEG did not
stimulate ROS production (–0.97 ± 3.74%) suggesting that the
respiratory burst caused by the immunogene was mediated by
speciﬁc receptors on the microglial membrane.
Further, aggregation of the OX42-immunogene as seen by DLS
(Figures 8A,B) was crucial to trigger the respiratory burst, because
OX42 antibody alone (2.57 ± 1.68%) and the non-aggregated
OX42-immunoporter stimulated only low levels of ROS produc-
tion (9.83 ± 2.84%). Particulate zymosan as a positive control
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FIGURE 7 |The OX42-immunogene does not cause gene
expression in vivo. (A) Representative confocal images show the
OX42-immunogene injected into the right lateral ventricle caused an
increase in green ﬂuorescence that co-localized in Iba1-IR microglia
which exhibited an amoeboid shape (yellow arrow heads). (B) Confocal
imaging of brain sections (dorsal striatum) revealed that the green
ﬂuorescence observed is non-speciﬁc, because non-speciﬁc
ﬂuorescence was also seen in the red ﬁlter in absence of red
ﬂuorophore-labeled cell markers. Further, an anti-EGFP antibody did
not detect EGFP-expression.
generated signiﬁcant levels of ROS (45.8± 4.7%,P < 0.01) similar
to the aggregated OX42-immunogene. Therefore, the aggregated
OX42-immunogene triggered a strong inﬂammatory response in
microglia as demonstrated by a phagocytosis-induced respiratory
burst.
CHLOROQUINE FACILITATES ENDOSOMAL ESCAPE IN MICROGLIA
Dynamic light scattering data and the ROS assay showed that
the OX42-immunogene formed large complexes with the abil-
ity to trigger phagocytosis and an unwanted immune response
that potentially is linked to intracellular destruction of the
immunogene. However, this data did not explain why non-
targeting PEI–PEG in absence of the respiratory burst did not
cause gene expression in microglia, although PEI–PEG was taken
up by microglial cells (Figures 5A,B and 6). Thus, we examined
limited endosomal escape as an additional barrier to non-viral
gene delivery into microglia.
Mixed glia cultures were transfected with PEI–PEG and the
OX42-immunogene in the presence of the endosomolytic agent
chloroquine. Chloroquine treatment signiﬁcantly increased the
total number of cells transfected with PEI–PEG (424 ± 42 vs.
74 ± 13, P < 0.0001) and the OX42-immunogene (71 ± 8
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FIGURE 8 |The OX42-immunogene forms large aggregates and triggers
an immune response in microglia. (A) Comparison of the size-distribution
proﬁles between complete cell culture medium (DMEM + 10% FBS) and the
OX42-immunoporter obtained by DLS shows that the non-viral vehicle did not
form aggregates. After adding pDNA to form the OX42-immunogene
(N/P = 4), aggregates formed over a large range (≈50–1300 nm). (B) Adding
FBS to polyplexes after maturation in HBS and maturation of polyplexes in
FBS-containing medium caused a shift in size-distribution to lower aggregate
sizes, but it had no effect on the width of size-distributions. Values are plotted
as Mean ± SEM (two experiments). FBS, fetal bovine serum; OX42-IP,
OX42-immunoporter; HBS, HEPES-buffered saline; D (+/–), DMEM
with/without 10% FBS. (C) ROS production in microglial cells was measured
by quantifying ROS-indicator ﬂuorescence after 60 min and reported as
percentage (%) of the internal standard PDBu. The aggregated
OX42-immunogene triggered the respiratory burst (38.8 ± 3.3%) which was
inhibited by the respiratory burst inhibitor diphenyliodonium (–7.02 ± 4.49%).
The positive control zymosan caused the release of ROS at similar levels
(45.8 ± 4.7%) to the OX42-immunogene. However, PEI–PEG
(–0.97 ± 3.74%), OX42 antibody (2.57 ± 1.68%) and the OX42-immunoporter
(9.83 ± 2.84%) did not trigger signiﬁcant ROS production. Values are plotted
as Mean ± SEM. **P < 0.01 vs. control; ****P < 0.0001 vs. control; N.S.,
not signiﬁcant. DPI, diphenyliodonium; PDBu, phorbol 12,13-dibutyrate.
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vs. 8 ± 3, P < 0.0001) at N/P = 4 (Figure 9A). Interestingly,
chloroquine caused a signiﬁcant increase in the percentage of
transfected cells for both transfectants that were microglia (PEI–
PEG: 20.3 ± 1.2% vs. 14.3 ± 1.7%, P < 0.05; OX42-immunogene:
32.3 ± 2.4% vs. 12.7 ± 8.0%, P < 0.05; Figure 9B) demon-
strating that endosomal escape is limiting for non-viral gene
transfer into microglia. However, despite this increase in presence
FIGURE 9 |The ability of PEI to facilitate intracellular escape in
microglia is limited. (A) PEI–PEG (424 ± 42 vs. 74 ± 13) and the
aggregated OX42-immunogene (71 ± 8 vs. 8 ± 3) transfected signiﬁcantly
more cells in the presence of chloroquine. (B) Chloroquine also increased
speciﬁcity for microglia when transfected with PEI–PEG (20.3 ± 1.2% vs.
14.3 ± 1.7%) and the OX42-immunogene (32.3 ± 2.4% vs. 12.7 ± 8.0%).
Values are plotted as Mean ± SEM. n = 6 coverslips (three independent
experiments). *P < 0.05, ****P < 0.0001. Cq, chloroquine.
of chloroquine the majority of the cells transfected with the
OX42-immunogene were still not microglia. This showed that
the OX42-immunogene is not entirely speciﬁc for microglia and
the data strongly suggested the involvement of another route in
internalization of the OX42-immunogene other than CD11b, for
instance a receptor which is shared by microglia and other glial
cells.
DISCUSSION
This study took a systematic approach at examining the use
of antibody-based non-viral vehicles for microglia-speciﬁc gene
transfer. Double-labeling experiments in mixed cultures were
performed with OX42 antibody and markers for the two most
abundant cell types in mixed glia culture – GFAP for astrocytes
and Iba1 for microglia. The experiments clearly demonstrated the
speciﬁcity of CD11b formicroglia. This is consistent with previous
reports (Akiyama and McGeer, 1990) and accounts for the use of
OX42 antibody as a selective microglial marker for immunocyto-
chemistry and IHC. In vivo data conﬁrmed the speciﬁcity of OX42
antibody for microglia and the absence of X63-binding strongly
suggests attachment of OX42 to microglia via the CD11b receptor.
Because microglia and other cells within the CNS express Fcγ-
receptors (Ulvestad et al., 1994; Vedeler et al., 1994; Okun et al.,
2010) that can bind antibodies and are also capable of ingesting
extracellular material by pinocytosis (Booth and Thomas, 1991;
Ward et al., 1991), the absence of these alternative internalization
mechanisms is essential for speciﬁc gene transfer into microglia
via CD11b.
The usefulness of the OX42 antibody was further empha-
sized by its property to be rapidly internalized into microglia.
The negative control antibody X63 did not bind and was not
taken up by microglia demonstrating that internalization of
OX42 must occur via the extracellular domain of the CD11b
receptor. Direct immunoﬂuorescence studies and co-labeling
with Lysotracker Red, a marker for acidic late endosomes and
lysosomes, further showed that the internalized antibody was
trafﬁcked to acidic organelles in the perinuclear cytoplasm. The
known perinuclear localization of lysosomes and late endo-
somes (Huotari and Helenius, 2011) agreed with the localization
of OX42-ﬂuorescence seen here conﬁrming lysosomal trafﬁck-
ing of OX42 antibody in microglia. Lysosomal trafﬁcking is
desirable for non-viral vehicles that utilize PEI as DNA con-
densation agent, because the gradual acidiﬁcation of endosomes
facilitates the endosomal escape of the gene vehicle (Varkouhi
et al., 2011). The proximity of lysosomes to the cell nucleus
also improves transfection efﬁciency by reducing the spatial dis-
tance from endosome exit to nucleus entry (Forrest and Pack,
2002).
Since we demonstrated the usefulness of the OX42 antibody
as microglia-speciﬁc ligand, a bioconjugate was developed based
on the OX42 antibody and branched PEI of 25 kDa engrafted
with PEG. The resulting OX42-immunoporter showed complete
DNA-binding at a N/P-ratio of 5 as demonstrated in gel retar-
dation assays. Subsequent transfection experiments were carried
out at N/P = 4 to avoid an excess of PEI that can cause com-
peting non-speciﬁc uptake mechanisms via positively charged
PEI (Kircheis et al., 2001; Payne et al., 2007). Further, initial
Frontiers in Molecular Neuroscience www.frontiersin.org October 2014 | Volume 7 | Article 79 | 14
Smolny et al. Gene transfer into microglia via CD11b
transfection experiments with PEI–PEG at N/P = 10 reduced
the number of transfected cells and appeared to have toxic
effects in mixed glia culture as judged by the up-regulation
of GFAP expression and morphology of astrocytes (data not
shown).
The conjugation of the OX42 antibody to PEI–PEG caused sig-
niﬁcant reduction of off-target transfection of PEI–PEG in vitro.
However, the OX42-immunogene transfected only few cells with
no apparent increase in speciﬁcity for microglia. Expression of
EGFP was mostly absent in microglia regardless of whether PEI–
PEG or the OX42-immunogene was used for transfection in vitro
and in vivo. Thiswasdemonstratedby the absenceof EGFP-IRwith
an anti-EGFP antibody and by the observed pattern for green ﬂu-
orescence of high intensity (EGFP, cytoplasmic and nuclear) and
low intensity (non-speciﬁc, vesicle-like and perinuclear). Treat-
ing mixed glia cultures with PEI–PEG or the OX42-immunogene
carrying a control vector that lacked the EGFP reporter gene
then conﬁrmed that the polyplexes were taken up by microglia
and that the intracellular non-speciﬁc ﬂuorescence is unrelated
to EGFP expression. Thus, the non-speciﬁc ﬂuorescence was
thought to be related to an intracellular event downstream of
internalization.
Previous work showed that cultured microglial cells exhibit
non-speciﬁc ﬂuorescence when treated with extracellular mate-
rial destined for intracellular degradation (Stolzing et al., 2002).
Importantly, microglia were shown to degrade only mildly
oxidized protein efﬁciently while strongly oxidized proteins
were accumulated intracellular and exhibited broad-spectrum
auto-ﬂuorescence (Stolzing et al., 2002). Incompletely degraded
material that causes non-speciﬁc ﬂuorescence has been termed
“lipofuscin” (Sitte et al., 2000; Stolzing et al., 2002; Lei et al.,
2012). The increase in non-speciﬁc, lipofuscin-like ﬂuorescence
in microglia therefore most likely originates from internaliza-
tion and accumulation of incompletely degraded PEI–PEG and
OX42-immunogene. The perinuclear localization of this vesicle-
like, non-speciﬁc ﬂuorescence suggests that microglia degrade
the polyplexes in lysosomes. The observed amoeboid, phagocytic
shape of microglia in vivo further indicates thatmicroglia internal-
ize the polyplexes by phagocytosis rather than receptor-mediated
endocytosis.
Dynamic light scattering showed that the OX42-immunogene
formed a heterogeneous population of aggregated polyplexes
from less than 100 nm to more than 1 μm in diameter. This
demonstrated that phagocytosis is one of the mechanisms by
which the OX42-immunogene can be internalized. The stimu-
lation of a respiratory burst demonstrated that the aggregated
OX42-immunogene but not PEI–PEG and the OX42 antibody
alone triggers a strong inﬂammatory response in microglia.
Clearly, stimulation of an immune response is unwanted not
only because this most likely trigger functions in microglia asso-
ciated with their role as scavengers and cause destruction of the
OX42-immunogene, but also because of potential exacerbation of
neurodegeneration.
The data on ROS generation further gave evidence that the
phagocytosis-induced respiratory burst not only requires aggre-
gated large particles, but also receptors on the cell surface. Since the
OX42-immunogene was developed to target CD11b on microglia
and to undergo receptor-mediated endocytosis, aggregation of the
OX42-immunogene most likely caused the stimulation of other
receptors such as FcγR which require receptor cross-linking by
antibody-coated targets (reviewed in Nimmerjahn and Ravetch,
2008). The OX42-immunogene may have mimicked antibody-
coated immune complexes cleared by the phagocytic system of
microglial cells. This could have occurred via phagocytosis recep-
tors including CD11b and Fcγ-receptors as previously reported
for macrophages (Thornton et al., 1996; Xia et al., 1999; Huang
et al., 2011) that perform functions closely related to microglial
cells.
Previous work on peripheral immune cells related to microglia
revealed that CD11b and FcγRs interact to facilitate the rate of
phagocytosis (Mantovani et al., 1972; Mantovani, 1975; Jongstra-
Bilen et al., 2003; Huang et al., 2011). This observation becomes
even more important when the binding site of OX42 on CD11b
is considered. The OX42 antibody is suggested to bind to, or close
to, the complement-binding site of CD11b (Robinson et al., 1986;
Klegeris and McGeer, 1994; Sohn et al., 2003) which is impor-
tant for phagocytosis of complement-coated apoptotic cells in
absence of cytotoxic immune effector functions (Amarilyo et al.,
2010; Hughes et al., 2010; Ricklin et al., 2010). The initiation
of a respiratory burst therefore strongly argues for the involve-
ment of FcγRs in uptake of the OX42-immunogene. Thus, the
inability of the OX42-immunogene to cause substantial gene
expression in microglia may be due to targeting receptors other
than CD11b and directing the gene vehicle to a less efﬁcient
gene delivery pathway for microglial cells such as FcγR-mediated
phagocytosis.
While the respiratory burst elicited by the aggregated OX42-
immunogene limits its use for microglial gene transfer, non-
targeting PEI–PEG at N/P = 4 did not cause substantial gene
expression in microglia either albeit the absence of ROS pro-
duction. Interestingly, PEI–PEG was more successful in gene
transfer in vitro, although most of the transfected cells were
astrocytes. PEI–PEG did not transfect any cells in vivo and
was predominantly taken up by microglial cells with subse-
quent intracellular degradation. The unsuccessful transfection
of microglia with PEI–PEG in vivo is consistent with a pre-
vious report that used N/P-ratios as high as 15 (Kwon et al.,
2010). However, the difﬁculty of transfecting brain cells with
non-viral vehicles in vivo may not be limited to PEI–PEG,
because a novel cationic polymer that showed high transfec-
tion efﬁciency in culture was able to increase gene transfer in
vivo only slightly as compared to naked DNA (Newland et al.,
2014). The phagocytic/amoeboid morphology and expression
of Iba1 on the cell membrane (Ohsawa et al., 2000) further
suggested that PEI–PEG also stimulated microglial activation,
although through apparent different mechanisms compared to
the OX42-immunogene.
Data obtained by DLS hints at the sample preparation as deci-
sive factor for particle size and the internalization mechanism
triggered. PEI-polyplexes were prepared in physiological salt solu-
tion for in vivo injections. However, for in vitro transfections
these complexes were further diluted in complete cell culture
medium containing FBS. In accordance with studies performed
in other cell types (Ogris et al., 1998; Petersen et al., 2002; Neu
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et al., 2005), DLS data showed that sample preparation in general
and the presence of FBS in particular shifts polyplex aggregates to
smaller sizes that could favor endocytosis, at least for astrocytes.
Therefore, larger aggregates may have been injected in vivo that
shifted the internalization of PEI–PEG aggregates to professional
phagocytes that take up large aggregates and destroy them such as
microglia. While phagocytosis is a receptor-mediated internaliza-
tion mechanism, non-speciﬁc internalization mechanisms such
as macropinocytosis (Mayor and Pagano, 2007; Hufnagel et al.,
2009; Xiang et al., 2012) may have occurred which is usually con-
ﬁned to immune cells such as macrophages and microglia (Kerr
and Teasdale, 2009; Mandrekar et al., 2009; Mercer and Helenius,
2009).
The inability of PEI–PEG in this study to transfect a large
number of microglia as compared to astrocytes point to differ-
ent internalization mechanisms between these glia cells and the
ineffectiveness of branched PEI (bPEI, 25 kDa) in promoting
endosomal escape and gene transfer in microglia. This notion is
further supported by the observation that in presence of chloro-
quine, a drug used previously to promote endosomal escape and
enhance transfection efﬁciency of non-viral vehicles in other cell
types (Erbacher et al., 1996; Ogris et al., 1998; Blessing et al.,
2001), PEI–PEG and the OX42-immunogene transfected signif-
icantly more cells including microglia in vitro. Indeed, the success
of gene transfer with PEI depends on polyplex type (linear or
branched PEI, molecular weight) and the cell type transfected
(Kircheis et al., 1997; Ogris et al., 1998; von Gersdorff et al.,
2006; Intra and Salem, 2008) and may need to be optimized
for microglial gene transfer. However, more than 60% of trans-
fected cells in presence of chloroquine were not microglia even
when cells were transfected with the OX42-immunogene. This
supports the assumption that the aggregated OX42-immunogene
not only targets the CD11b receptor but also FcγRs, because astro-
cytes and other brain cells express at least one FcγR subtype in
vitro and in vivo (Nitta et al., 1992; Li et al., 2008; Okun et al.,
2010).
CONCLUSION
This study highlighted for the ﬁrst time the CD11b receptor
as a potential target for non-viral gene transfer into microglia
with antibodies. Data presented here show that the anti-CD11b
antibody OX42 is speciﬁc for microglia, is rapidly internalized,
trafﬁcked to lysosomes and does not elicit a strong immune
response. This study also demonstrates that the synthesis of a
microglia-targeting non-viral vehicle can be accomplished. How-
ever, the absence of substantial reporter gene expression in
microglia in vitro and in vivo demonstrates that microglia is dif-
ﬁcult to transfect with non-viral vehicles based on branched PEI
of 25 kDa. While PEI–PEG and the OX42-immunogene are both
internalized into microglia, they both are subject to intracellular
degradation.
Two barriers to receptor-mediated gene transfer into microglia
were characterized that will help to further develop second gen-
eration immunogenes targeting microglial cells. Bypassing FcγR-
mediated phagocytosis and the respiratory burst will require the
use of OX42-F(ab’)2 antibody fragments that lack FcγR-binding
sites. These antibody fragments should also increase speciﬁcity
toward CD11b and microglia by avoiding cross-reaction with
other cells that express FcγRs. The inability of PEI–PEG to cause
substantial gene expression in microglia demonstrates that endo-
somal escape is another barrier for non-viral gene transfer into
microglia and that alternative PEI-polymers may be required that
give higher levels of gene expression in microglia. This study sug-
gests that phagocytosis is not an efﬁcient pathway for microglial
transfection. However, it remains to be establishedwhether phago-
cytosis via CD11b in absence of an immune response is able to
deliver genes into microglia.
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